Diabetic Neuropathic Pain Drug Pipeline Analysis Report 2024

Report Coverage

The Diabetic Neuropathic Pain Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into diabetic neuropathic pain drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for diabetic neuropathic pain. The report includes the analysis of over 100 pipeline drugs and 50+ companies. Diabetic neuropathic pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from diabetic neuropathic pain.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to diabetic neuropathic pain are covered.

Diabetic Neuropathic Pain Drug Pipeline Outlook

Diabetic neuropathy is a common complication of diabetes. It affects as many as 50% of people suffering from type 1 and type 2 diabetes. Involves the signs of peripheral nerve dysfunction in people suffering from diabetes. Distal polyneuropathy becomes symptomatic in type 1 diabetes after long years of chronic prolonged hyperglycemia. While in type 2 diabetes, it is apparent after a few years of poor glycemic control, or even at diagnosis. Its symptoms include distal or more focal weakness and affects, the gastrointestinal cardiovascular systems and sweat glands, among others. There are four types of diabetes-related neuropathy including peripheral, proximal, autonomic, and focal. Peripheral neuropathy usually affects the legs and feet, and autonomic neuropathy affects the digestive system but can also affect the blood vessels, and urinary system. Proximal neuropathy affects thighs, hips, or buttocks and focal neuropathy affects specific nerves in the head, torso, or leg. The diagnosis of diabetic neuropathy can be done through laboratory tests which include hemoglobin A1c, thyroid function tests, vitamin B-12 and folate levels, C-reactive protein, rapid plasma regain, erythrocyte sedimentation rate, and antinuclear antibody among others.

The treatment for diabetic neuropathic pain includes oral medications such as antidepressants and anticonvulsant drugs. Pregabalin is also prescribed for the treatment of diabetic neuropathic pain as per the guidelines issued by the American Academy of Neurology and the American Academy of Physical Medicine and Rehabilitation. Additionally, gabapentin and sodium valproate are also given for diabetic neuropathy pain management. After several clinical evaluations, gabapentin proved a significant pain relief in patients suffering from chronic neuropathic pain.

Other drugs given to treat the condition include dextromethorphan, tramadol, morphine sulfate, and oxycodone. To patients, where oral medications are a concern, topical therapy with capsaicin or transdermal lidocaine are useful. In clinical trials, capsaicin has been proven effective in reducing pain associated with diabetic neuropathic. In some other clinical trials, duloxetine's effects on painful diabetic peripheral neuropathy were studied and showed positive results in the reduction of pain. These increasing clinical trials and changing dynamics are impacting the diabetic neuropathic pain clinical trial landscape significantly.

Diabetic Neuropathic Pain – Drug Pipeline Therapeutic Assessment

Diabetic Neuropathic Pain – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for diabetic neuropathic pain.

Diabetic Neuropathic Pain – Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under diabetic neuropathic pain pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. Lexicon Pharmaceuticals is conducting a phase II clinical trial for LX9211, which is an orally delivered small molecule compound. Pre-clinical studies showed that the drug was effective for the reduction of neuropathic pain. Moreover, the drug has received fast-track designation from the United States FDA. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for diabetic neuropathic pain.

Diabetic Neuropathic Pain Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the diabetic neuropathic pain pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in diabetic neuropathic pain clinical trials:

• Bial - Portela C S.A.
• Eli Lilly and Company
• Rigshospitalet, Denmark
• AbbVie
• Swedish Orphan Biovitrum
• NeuraLace Medical, Inc.
• Merck Sharp & Dohme LLC
• Bristol-Myers Squibb
• Nevro Corp
• CSPC Ouyi Pharmaceutical Co., Ltd.
• Lexicon Pharmaceuticals
• Syqe Medical
• Haisco Pharmaceutical Group Co., Ltd.
• Daiichi Sankyo Co., Ltd.
• Janssen Pharmaceutical K.K.
• Others

Diabetic Neuropathic Pain – Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Duloxetine

The trial is designed to assess the safety of duloxetine 60 milligrams daily in patients with diabetic peripheral neuropathic pain. The trial is sponsored by Eli Lilly and Company and is currently under phase III.

ABT-652 6 mg

The objective of the study is to assess the safety of ABT-652 compared to placebo in patients with diabetic neuropathic pain. The trial is sponsored by AbbVie and is currently under phase II.

BVT.115959

Swedish Orphan Biovitrum is developing the drug and is currently under phase II. The study being conducted to evaluate the safety of BVT.115959 in diabetic patients suffering from neuropathic pain who are not taking analgesics.

Reasons To Buy This Report

The Diabetic Neuropathic Pain Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for diabetic neuropathic pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within diabetic neuropathic pain pipeline insights.

Key Questions Answered in the Diabetic Neuropathic Pain – Pipeline Insight Report

• What is the current landscape of diabetic neuropathic pain pipeline drugs?
• How many companies are developing diabetic neuropathic pain?
• How many phase III and phase IV drugs are currently present in diabetic neuropathic pain pipeline drugs?
• Which companies/institutions are leading the diabetic neuropathic pain development?
• What is the efficacy and safety profile of diabetic neuropathic pain pipeline drugs?
• What are the opportunities and challenges present in the diabetic neuropathic pain pipeline landscape?
• Which company is conducting major trials for diabetic neuropathic pain?
• What geographies are covered for diabetic neuropathic pain clinical trials?
• What are emerging trends in diabetic neuropathic pain clinical trials?

Related Reports

Global Diabetic Neuropathy Market

Global Peripheral Neuropathy Treatment Market

Global Diabetic Gastroparesis Treatment Market